Khan A, Mirolo M H, Claypoole K, Bhang J, Cox G, Horita A, Tucker G
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle 98195.
Am J Psychiatry. 1994 Nov;151(11):1694-6. doi: 10.1176/ajp.151.11.1694.
A low dose (0.5 mg) of thyrotropin-releasing hormone (TRH), a short-acting tripeptide with known analeptic properties, was administered to eight depressed patients 5 minutes after ECT session 3 or 4 in a double-blind, placebo-controlled crossover design. After TRH infusion the patients displayed selectively better performance on a battery of neuropsychological tests than they did after placebo infusion. Further exploration with pharmacological probes to mitigate ECT postictal cognitive deficits is warranted.
在双盲、安慰剂对照的交叉设计中，对8名抑郁症患者在第3次或第4次ECT治疗后5分钟给予低剂量（0.5毫克）促甲状腺激素释放激素（TRH），这是一种具有已知兴奋特性的短效三肽。输注TRH后，患者在一系列神经心理学测试中的表现比输注安慰剂后有选择性地更好。有必要进一步探索使用药理学探针来减轻ECT发作后认知缺陷。
